Open study with (-)-OSU6162 in multiple sclerosis-related fatigue.

Sara HaghighiSara ForsmarkArvid CarlssonMarie K L NilssonMaria L CarlssonRobert C SchuitCarl-Gerhard Gottfries

Published in: Acta neurologica Scandinavica (2018)

In view of its good tolerability, (-)-OSU6162 may offer a new treatment option for alleviating mental fatigue, as well as depression, in MS. Larger, randomized double-blind controlled trials are warranted to confirm the present preliminary observations.

Keyphrases

double blind
placebo controlled
multiple sclerosis
sleep quality
open label
clinical trial
phase iii
phase ii
mass spectrometry
depressive symptoms
mental health
minimally invasive
white matter
ms ms
randomized controlled trial